China SXT Pharmaceuticals, Inc. — Revenue by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/2ba67b67-a491-45c2-a050-0719dc767068/serie/revenue
| Fiscal year | Revenue | Period | Evidence |
|---|---|---|---|
| FY 2025 | $1.1M | 2025-04-01 – 2026-03-31 | evidence 0001213900-26-074310 |
| FY 2024 | $1.7M | 2024-04-01 – 2025-03-31 | evidence 0001213900-25-069688 |
| FY 2023 | $1.9M | 2023-04-01 – 2024-03-31 | evidence 0001213900-25-069688 |
| FY 2022 | $2.0M | 2022-04-01 – 2023-03-31 | evidence 0001213900-25-069688 |
| FY 2021 | $2.6M | 2021-04-01 – 2022-03-31 | evidence 0001213900-22-039838 |
| FY 2020 | $4.8M | 2020-04-01 – 2021-03-31 | evidence 0001213900-21-042555 |
| FY 2019 | $5.2M | 2019-04-01 – 2020-03-31 | evidence 0001213900-20-019503 |
| FY 2018 | $7.0M | 2018-04-01 – 2019-03-31 | evidence 0001213900-19-016026 |
| FY 2017 | $7.0M | 2017-04-01 – 2018-03-31 | evidence 0001213900-19-016026 |
| FY 2016 | $4.9M | 2016-04-01 – 2017-03-31 | evidence 0001213900-19-016026 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
China SXT Pharmaceuticals, Inc. — all facts · Net Income · Operating Income